EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling

Matteo Costacurta, Jarrod J Sandow, Belinda Maher, Olivia Susanto, Stephin J Vervoort, Jennifer R Devlin, Daniel Garama, Mark R Condina, Joel R Steele, Hossein V Kahrood, Daniel Gough, Ricky W Johnstone und 1 weitere

The FEBS Journal · 2024

DOI: 10.1111/febs.17196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FEBS Journal, 2024. Verfasst von Matteo Costacurta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Monash Haematology, Monash Health, Clayton, Australia. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Ubiquitin-Protein Ligases, Bortezomib. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Family of Mr Lawrence Bode, National Health and Medical Research Council, Monash Haematology Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunomodulatory imide drugs (IMiDs) are central components of therapy for multiple myeloma (MM). IMiDs bind cereblon (CRBN), an adaptor for the CUL4‐DDB1‐RBX1 E3 ligase to change its substrate specificity and induce degradation of ‘neosubstrate’ transcription factors that are essential to MM cells. Mechanistic studies to date have largely focussed on mediators of therapeutic activity and insight into clinical IMiD toxicities is less developed. We adopted BioID2‐dependent proximity labelling (BioID2‐CRBN) to characterise the CRBN interactome in the presence and absence of various IMiDs and the proteasome inhibitor, bortezomib. We aimed to leverage this technology to further map CRBN interactions beyond what has been achieved by conventional proteomic techniques. In support of this approach, analysis of cells expressing BioID2‐CRBN following IMiD treatment displayed biotinylation of known CRBN interactors and neosubstrates. We observed that bortezomib alone significantly modifies the CRBN interactome. Proximity labelling also suggested that IMiDs augment the interaction between CRBN and proteins that are not degraded, thus designating ‘neointeractors’ distinct from previously disclosed ‘neosubstrates’. Here we identify Non‐Muscle Myosin Heavy Chain IIA (MYH9) as a putative CRBN neointeractor that may contribute to the haematological toxicity of IMiDs. These studies provide proof of concept for proximity labelling technologies in the mechanistic profiling of IMiDs and related E3‐ligase‐modulating drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adaptor Proteins, Signal TransducingUbiquitin-Protein LigasesBortezomibHumansMultiple MyelomaCell Line, TumorThalidomideProtein Interaction MapsProteomicsImmunologic FactorsLenalidomideProtein Interaction Mapping

Stichwörter der Autor:innen

BioID2IMiDsbortezomibcereblonmyosin

Substanzen

Adaptor Proteins, Signal TransducingCRBN protein, humanUbiquitin-Protein LigasesBortezomibThalidomideImmunologic FactorsLenalidomide

Autor:innen und Institutionen

  • Monash Haematology, Monash Health, Clayton, Australia.
  • Blood Cancer Therapeutics Laboratory, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
  • The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
  • Department of Medical Biology, The University of Melbourne, Parkville, Australia.
  • Translational Haematology Program, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.

ORCID-Profile: Jake Shortt

Förderung

  • Family of Mr Lawrence Bode
  • National Health and Medical Research Council
  • Monash Haematology Research Grant

Zitieren

APA

Costacurta, M., Sandow, J. J., Maher, B., Susanto, O., Vervoort, S. J., Devlin, J. R., Garama, D., Condina, M. R., Steele, J. R., Kahrood, H. V., Gough, D., Johnstone, R. W., & Shortt, J. (2024). Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling. The FEBS Journal. https://doi.org/10.1111/febs.17196

Vancouver

Costacurta M, Sandow JJ, Maher B, Susanto O, Vervoort SJ, Devlin JR, et al. Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling. The FEBS Journal. 2024. doi:10.1111/febs.17196

BibTeX
@article{Costacurta2024,
  author = {Costacurta, Matteo and Sandow, Jarrod J and Maher, Belinda and Susanto, Olivia and Vervoort, Stephin J and Devlin, Jennifer R and Garama, Daniel and Condina, Mark R and Steele, Joel R and Kahrood, Hossein V and Gough, Daniel and Johnstone, Ricky W and Shortt, Jake},
  title = {Mapping the IM i D ‐dependent cereblon interactome using B io ID ‐proximity labelling},
  journal = {The FEBS Journal},
  year = {2024},
  doi = {10.1111/febs.17196}
}
Kostenlos starten →